Aptamer Group Plc (GB:APTA)
LSE:APTA
Want to see GB:APTA full AI Analyst Report?
APTA Stock Chart & Stats
0.80 p
-0.01 p(-2.86%)
At close: 4:00 PM EST
0.80 p
-0.01 p(-2.86%)
Day’s Range― - ―
52-Week Range0.30 p - 1.57 p
Previous CloseN/A
Volume3.91M
Average Volume (3M)15.29M
Market Cap
£19.00M
Enterprise Value14.90M
Total Cash (Recent Filing)£1.53M
Total Debt (Recent Filing)£333.00K
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume14,821,052
30 Day Avg. Volume15,285,032
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Aptamer PlatformAptamer Group's proprietary aptamer discovery and product platform creates a durable technical moat. Platform applicability across diagnostics, therapeutics and bioprocessing supports multiple long-term revenue avenues, licensing and collaborations as adopters seek specific, synthetic binders.
Diversified End-market ExposureServing diagnostics, therapeutics and research/bioprocessing reduces single-market dependence and supports multi-channel commercialisation. This structural exposure allows the company to capture demand across sectors, smoothing revenue cycles and enabling cross-market product leverage.
Improving Leverage PositionAn improved debt-to-equity ratio enhances financial flexibility and reduces immediate solvency risk, giving management longer runway to execute R&D and commercial plans. Better leverage supports ability to raise capital on more favorable terms if needed.
Bears Say
Severe Revenue CollapseA near-total revenue collapse is a fundamental commercial red flag: it undermines scale economics, erodes customer traction, and weakens bargaining power with partners. Sustained low sales make profitable commercialization and R&D funding difficult without external financing.
Persistent Negative Cash FlowContinued negative operating and free cash flows indicate cash burn that will require recurring financing or partner deals. That reduces strategic optionality, risks dilution, and limits the company's ability to invest consistently in commercialization and product development.
Ongoing Losses And Negative ROESustained losses and negative ROE signal the business is not generating returns on shareholder capital. Over time this impedes reinvestment, deters institutional partners and makes it harder to attract long-term investors, threatening viability absent structural recovery.
Aptamer Group Plc News
APTA FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest share price was 0.30 p and its highest was 1.57 p in the past 12 months.
What is Aptamer Group Plc’s market cap?
Aptamer Group Plc’s market cap is £19.00M.
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 20, 2026 which is in 142 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 25, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 3,455,144,000 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in GB:APTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptamer Group Plc
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom and internationally. The company's binders engineered to address issues which founds with molecules, such as antibodies; and offers solutions to bioprocessing, diagnostic, and pharmaceutical scientists. It serves pharma companies, diagnostic development companies, and research institutes. The company was incorporated in 2014 and is based in York, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―
Options Prices
Currently, No data available
---